PROTAC-based nanoantigens promote cross-presentation and trafficking of dendritic cell vaccine for enhanced antitumor efficacy
Together, we established a proof of concept for PROTAC in the DC vaccine design by linking E3 ligase to a protein model antigen, which can be readily replaced with other identified pathogenic antigens to elicit robust cytotoxic immune responses against tumors or viral diseases, and thus has serious implications in the clinics.
Authors
- Yijie Li (ORCID: https://orcid.org/0009-0004-3636-9624)
- Jinyao Li (ORCID: https://orcid.org/0000-0002-3295-6096)
- Yuekang Xu (ORCID: https://orcid.org/0000-0002-1100-3982)
- Zhe Zhou (ORCID: https://orcid.org/0000-0003-0869-2112)
- Peng Liu (ORCID: https://orcid.org/0009-0001-9100-4706)
- Tingting Zhang (ORCID: https://orcid.org/0000-0002-7868-9624)
- Xia Su (ORCID: https://orcid.org/0009-0008-1628-8199)
Institutions
- Xinjiang University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-012405
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00